SMAD5抗体

+ +

•  

   

     Western blot analysis using SMAD5 mouse mAb against Hela (1), SK-N-SH (2), PC-12 (3), Jurkat (4), and K562 (5) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of NTERA-2 cells using SMAD5 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using SMAD5 mouse mAb (green) and negative control (purple).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human brain tissues (left) and lung cancer tissues (right) using SMAD5 mouse mAb with DAB staining.    

  
  

SMAD5 antibody is a crucial tool in studying the TGF-β/BMP signaling pathway, which regulates diverse cellular processes, including proliferation, differentiation, apoptosis, and embryonic development. SMAD5. a member of the receptor-regulated SMAD (R-SMAD) family, is primarily activated by bone morphogenetic proteins (BMPs) through phosphorylation of its C-terminal SSXS motif. Upon activation, SMAD5 forms complexes with SMAD4 and translocates to the nucleus to modulate target gene expression.

Antibodies targeting SMAD5 are widely used in research to detect its expression, phosphorylation status, and subcellular localization. These antibodies are essential for techniques like Western blotting, immunoprecipitation, and immunohistochemistry, enabling the investigation of SMAD5’s role in developmental biology, cancer (e.g., metastasis, resistance), and fibrotic diseases. Specificity is critical, as SMAD5 shares structural homology with other R-SMADs (e.g., SMAD1/8), requiring antibodies to distinguish unique epitopes. Validation via knockout controls or siRNA knockdown ensures reliability.

Research applications often focus on SMAD5’s dual roles: as a tumor suppressor in certain contexts or a promoter of pathological fibrosis. Dysregulation of SMAD5 has been linked to BMP-related disorders, such as vascular anomalies and skeletal defects. The antibody’s utility extends to drug discovery, where SMAD5 activity serves as a biomarker for therapeutic targeting in BMP pathway-associated diseases.